Suppr超能文献

管状跨膜蛋白 16A 通过抑制 PGC-1α 介导的糖尿病肾病中线粒体动态平衡促进肾小管间质纤维化。

Tubular TMEM16A promotes tubulointerstitial fibrosis by suppressing PGC-1α-mediated mitochondrial homeostasis in diabetic kidney disease.

机构信息

Department of Pediatrics, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Department of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.

出版信息

Cell Mol Life Sci. 2023 Nov 6;80(12):347. doi: 10.1007/s00018-023-05000-6.

Abstract

Tubulointerstitial fibrosis (TIF) plays a crucial role in the progression of diabetic kidney disease (DKD). However, the underlying molecular mechanisms remain obscure. The present study aimed to examine whether transmembrane member 16A (TMEM16A), a Ca-activated chloride channel, contributes to the development of TIF in DKD. Interestingly, we found that TMEM16A expression was significantly up-regulated in tubule of murine model of DKD, which was associated with development of TIF. In vivo inhibition of TMEM16A channel activity with specific inhibitors Ani9 effectively protects against TIF. Then, we found that TMEM16A activation induces tubular mitochondrial dysfunction in in vivo and in vitro models, with the evidence of the TMEM16A inhibition with specific inhibitor. Mechanically, TMEM16A mediated tubular mitochondrial dysfunction through inhibiting PGC-1α, whereas overexpression of PGC-1α could rescue the changes. In addition, TMEM16A-induced fibrogenesis was dependent on increased intracellular Cl, and reducing intracellular Cl significantly blunted high glucose-induced PGC-1α and profibrotic factors expression. Taken together, our studies demonstrated that tubular TMEM16A promotes TIF by suppressing PGC-1α-mediated mitochondrial homeostasis in DKD. Blockade of TMEM16A may serve as a novel therapeutic approach to ameliorate TIF.

摘要

肾小管间质性纤维化(TIF)在糖尿病肾病(DKD)的进展中起着至关重要的作用。然而,其潜在的分子机制尚不清楚。本研究旨在探讨钙激活氯离子通道跨膜成员 16A(TMEM16A)是否有助于 DKD 中 TIF 的发展。有趣的是,我们发现 TMEM16A 的表达在 DKD 小鼠模型的肾小管中显著上调,这与 TIF 的发展有关。用特异性抑制剂 Ani9 抑制 TMEM16A 通道活性可有效防止 TIF。然后,我们发现 TMEM16A 在体内和体外模型中诱导管状线粒体功能障碍,用特异性抑制剂抑制 TMEM16A 可证明这一点。在机制上,TMEM16A 通过抑制 PGC-1α 介导管状线粒体功能障碍,而过表达 PGC-1α 可以挽救这些变化。此外,TMEM16A 诱导的纤维化依赖于细胞内 Cl 的增加,而降低细胞内 Cl 可显著减弱高糖诱导的 PGC-1α 和促纤维化因子的表达。总之,我们的研究表明,肾小管 TMEM16A 通过抑制 PGC-1α 介导的线粒体动态平衡促进 DKD 中的 TIF。阻断 TMEM16A 可能是改善 TIF 的一种新的治疗方法。

相似文献

3
Blockade of TMEM16A protects against renal fibrosis by reducing intracellular Cl concentration.
Br J Pharmacol. 2022 Jun;179(12):3043-3060. doi: 10.1111/bph.15786. Epub 2022 Feb 24.
6
Berberine protects against diabetic kidney disease via promoting PGC-1α-regulated mitochondrial energy homeostasis.
Br J Pharmacol. 2020 Aug;177(16):3646-3661. doi: 10.1111/bph.14935. Epub 2020 Jul 7.
7
The Role of TLR4 on PGC-1-Mediated Oxidative Stress in Tubular Cell in Diabetic Kidney Disease.
Oxid Med Cell Longev. 2018 May 16;2018:6296802. doi: 10.1155/2018/6296802. eCollection 2018.
8
FoxO1-mediated inhibition of STAT1 alleviates tubulointerstitial fibrosis and tubule apoptosis in diabetic kidney disease.
EBioMedicine. 2019 Oct;48:491-504. doi: 10.1016/j.ebiom.2019.09.002. Epub 2019 Oct 16.
9
MicroRNA-26a alleviates tubulointerstitial fibrosis in diabetic kidney disease by targeting PAR4.
J Cell Mol Med. 2024 Feb;28(3):e18099. doi: 10.1111/jcmm.18099. Epub 2024 Jan 2.

本文引用的文献

1
Inhibition of TMEM16A improves cisplatin-induced acute kidney injury via preventing DRP1-mediated mitochondrial fission.
Acta Pharmacol Sin. 2023 Nov;44(11):2230-2242. doi: 10.1038/s41401-023-01122-6. Epub 2023 Jul 4.
2
Molecular pathways that drive diabetic kidney disease.
J Clin Invest. 2023 Feb 15;133(4):e165654. doi: 10.1172/JCI165654.
3
Targeting inflammation to treat diabetic kidney disease: the road to 2030.
Kidney Int. 2023 Feb;103(2):282-296. doi: 10.1016/j.kint.2022.10.030. Epub 2022 Dec 5.
4
GPR87 promotes renal tubulointerstitial fibrosis by accelerating glycolysis and mitochondrial injury.
Free Radic Biol Med. 2022 Aug 20;189:58-70. doi: 10.1016/j.freeradbiomed.2022.07.004. Epub 2022 Jul 14.
5
Sex and Gender Related Differences in Diabetic Kidney Disease.
Semin Nephrol. 2022 Mar;42(2):170-184. doi: 10.1016/j.semnephrol.2022.04.007.
6
Molecular mechanisms and therapeutic targets for diabetic kidney disease.
Kidney Int. 2022 Aug;102(2):248-260. doi: 10.1016/j.kint.2022.05.012. Epub 2022 Jun 3.
8
TMEM16A (ANO1) as a therapeutic target in cystic fibrosis.
Curr Opin Pharmacol. 2022 Jun;64:102206. doi: 10.1016/j.coph.2022.102206. Epub 2022 Mar 29.
9
Mitochondrial dysfunction in diabetic tubulopathy.
Metabolism. 2022 Jun;131:155195. doi: 10.1016/j.metabol.2022.155195. Epub 2022 Mar 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验